Ask AI
PROTACs in MBC

CE / CME

PROTAC ER Degraders in ER-Positive/HER2-Negative MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Addressing Unmet Needs

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: March 12, 2026

Expiration: September 11, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this text module, Adrienne G. Waks, MD, and Rita Nanda, MD, share their thoughts on the current standard of care (SoC) options for patients with estrogen receptor (ER)–positive/ HER2-negative metastatic breast cancer (MBC), including current unmet needs following progression during or after receipt of endocrine therapy (ET) in tumors with an ESR1 mutation.

The key points discussed in this activity are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with breast cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Which of the following most accurately describes the mechanism of action of PROTAC ER degraders compared with other ETs, including oral selective estrogen receptor degraders (SERDs)?

How confident are you in your answer?

Which of the following most accurately describes the findings from the VERITAC-2 trial of the PROTAC ER degrader vepdegestrant compared with injectable fulvestrant in patients with HR-positive/HER2-negative MBC?

How confident are you in your answer?

What percentage of patients with ER-positive/HER2-negative disease who progress while receiving ET carry an ESR1 mutation, which is a predominant mechanism of ET resistance?

How confident are you in your answer?

Which of the following describes the patient population being evaluated in the ongoing VERITAC-3 trial of vepdegestrant with palbociclib vs letrozole and palbociclib?

How confident are you in your answer?